Critical appraisal of cabazitaxel in the management of advanced prostate cancer

References

• JemalASiegelRXuJWardECancer StatisticsWiley Subscription Services, Inc., A Wiley Company2010
   Google Scholar
• WaylandHKelvinAMMichaelGAsheshBJPeterJRVirajAMStage IV prostate cancer: survival differences in clinical T4, nodal and metastatic diseaseJ Urol2010184251251820620410
   PubMed Web of Science ®Google Scholar
• HugginsCHodgesCVStudies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostateCancer Res194114293297
   Google Scholar
• HugginsCStevensREJrHodgesCVStudies on prostate cancer: II. The effects of castration on advanced carcinoma of the prostate glandArch Surg1941432209223
   Google Scholar
• Aragon-ChingJBWilliamsKMGulleyJLImpact of androgen-deprivation therapy on the immune system: implications for combination therapy of prostate cancerFront Biosci2007124957497117569623
   PubMed Web of Science ®Google Scholar
• EisenbergerMO’DwyerPFriedmanMGonadotropin hormone-releasing hormone analogues: a new therapeutic approach for prostatic carcinomaJ Clin Oncol1986434144242936872
   PubMed Web of Science ®Google Scholar
• ScherHKellyWFlutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancerJ Clin Oncol1993118156615727687666
   PubMed Web of Science ®Google Scholar
• ScherHLiebertzCKellyWBicalutamide for advanced prostate cancer: the natural versus treated history of diseaseJ Clin Oncol1997158292829389256137
   PubMed Web of Science ®Google Scholar
• PetrylakDPTangenCMHussainMHDocetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancerN Engl J Med2004351151513152015470214
   PubMed Web of Science ®Google Scholar
• TannockIFde WitRBerryWRDocetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancerN Engl J Med2004351151502151215470213
   PubMed Web of Science ®Google Scholar
• BertholdDRPondGRde WitREisenbergerMTannockIFSurvival and PSA response of patients in the TAX 327 study who crossed over to receive docetaxel after mitoxantrone or vice versaAnn Oncol200819101749175318487550
   PubMed Web of Science ®Google Scholar
• ArmstrongAJGarrett-MayerEde WitRTannockIEisenbergerMPrediction of survival following first-line chemotherapy in men with castration- resistant metastatic prostate cancerClinical Cancer Research201016120321120008841
   PubMed Web of Science ®Google Scholar
• LongoDLNew therapies for castration-resistant prostate cancerN Engl J Med.363547948120818868
   PubMed Web of Science ®Google Scholar
• KantoffPWHiganoCSShoreNDSipuleucel-T immuno-therapy for castration-resistant prostate cancerN Engl J Med363541142220818862
   PubMed Web of Science ®Google Scholar
• NCT0887198: Abiraterone acetate in asymptomatic or mildly symptomatic patients with metastatic castration-resistant prostate cancer http://www.clinicaltrials.govAccessed 2009 Jul 29
   Google Scholar
• NCT0638690: Abiraterone acetate in castration-resistant prostate cancer previously treated with docetaxel-based chemotherapy http://www.clinicaltrials.govAccessed 2009 Jul 29
   Google Scholar
• NCT1193257: A phase 3, randomized, double-blind, multicenter trial comparing orteronel plus prednisone with placebo plus prednisone in patients with metastatic castration-resistant prostate cancer that has progressed during or following docetaxel-based therapy http://www.clinicaltrials.govAccessed 2010 Oct 2
   Google Scholar
• AttardGReidAHMA’HernRSelective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancerJ Clin Oncol200927233742374819470933
   PubMed Web of Science ®Google Scholar
• AttardGReidAHMYapTAPhase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone drivenJ Clin Oncol200826284563457118645193
   PubMed Web of Science ®Google Scholar
• ScherHIBeerTMHiganoCSAntitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 studyLancet2010 Apr 437597241437144620398925
   PubMed Web of Science ®Google Scholar
• NCT0974311: AFFIRM: a multinational phase 3, randomized, double-blind, placebo-controlled efficacy and safety study of oral MDV3100 in patients with progressive castration-resistant prostate cancer previously treated with docetaxel-based chemotherapy http://www.clinicaltrials.govAccessed 2010 Oct 2
   Google Scholar
• de BonoJSLogothetisCFizaziKAbiraterone acetate plus low dose prednisone improves overall survival in patients with metastatic castration-resistant prostate cancer (CRPC) who have progressed after docetaxel-based chemotherapy: results of COU-AA-301, a randomized double-blind placebo-controlled phase 3 study2010 European Society for Medical Oncology (ESMO) Annual Meeting2010 Oct 11
   Google Scholar
• KumarNTaxol-induced polymerization of purified tubulin. Mechanism of actionJ Biol Chem19812562010435104416116707
   PubMed Web of Science ®Google Scholar
• CaplowMZeebergBDynamic properties of microtubules at steady state in the presence of taxolEur J Biochem198212723193246128228
   PubMedGoogle Scholar
• WhiteJRaoGEffects of a microtubule stabilizing agent on the response of platelets to vincristineBlood19826024744836124288
   PubMed Web of Science ®Google Scholar
• BisseryM-CBouchardHRiouJVrignaudPCombeauCBourzatJDPreclinical evaluation of TXD258, a new taxoidProceedings of the American Association for Cancer Research200041Abstract1364
   Google Scholar
• VrignaudPLejeunePChaplinDLavelleFBisseryMCIn vivo efficacy of TXD258, a new taxoid, against human tumor xenograftsProceedings of the American Association for Cancer Research200041Abstract1365
   Google Scholar
• StoneKRMickeyDDWunderliHMickeyGHPaulsonDFIsolation of a human prostate carcinoma cell line (DU 145)Int J Cancer1978213274281631930
   PubMed Web of Science ®Google Scholar
• ArchimbaudYGiresPPellerinRNicheleGPouletDPharmacokinetics of a new taxoid, 14C-TXD258, in blood, plasma and brain of the mouse, rat and dogProceedings of the American Association for Cancer Research200041Abstract1375
   Google Scholar
• CisterninoSBourassetFArchimbaudYSemiondDSanderinkGScherrmannJMNonlinear accumulation in the brain of the new taxoid TXD258 following saturation of P-glycoprotein at the blood-brain barrier in mice and ratsBr J Pharmacol200313871367137512711638
   PubMed Web of Science ®Google Scholar
• DykesDSarsatJBisseryMCEfficacy evaluation of TXD258, a taxoid compound against orthotopic and subcutaneous glioblastomasProceedings of the American Association for Cancer Research200041Abstract1916
   Google Scholar
• MitaACDenisLJRowinskyEKPhase I and pharmacokinetic study of XRP6258 (RPR 116258A), a novel taxane, administered as a 1-hour infusion every 3 weeks in patients with advanced solid tumorsClin Cancer Res200915272373019147780
   PubMed Web of Science ®Google Scholar
• DierasVLimentaniSRomieuGPhase II multicenter study of larotaxel (XRP9881), a novel taxoid, in patients with metastatic breast cancer who previously received taxane-based therapyAnn Oncol20081971255126018381372
   PubMed Web of Science ®Google Scholar
• Metzger-FilhoOMoulinCde AzambujaEAhmadALarotaxel: broadening the road with new taxanesExpert Opin Investig Drugs200918811831189
   PubMed Web of Science ®Google Scholar
• YamamotoNBokuNMinamiHPhase I study of larotaxel administered as a 1-h intravenous infusion every 3 weeks to Japanese patients with advanced solid tumoursCancer Chemother Pharmacol200965112913619437020
   PubMed Web of Science ®Google Scholar
• PivotXKoralewskiPHidalgoJLA multicenter phase II study of XRP6258 administered as a 1-h i.v. infusion every 3 weeks in taxane-resistant metastatic breast cancer patientsAnn Oncol20081991547155218436520
   PubMed Web of Science ®Google Scholar
• HortobagyiGNGomezHLLiRKAnalysis of overall survival from a phase III study of ixabepilone plus capecitabine versus capecitabine in patients with MBC resistant to anthracyclines and taxanesBreast Cancer Res Treat2010122240941820454927
   PubMed Web of Science ®Google Scholar
• De BonoJSOudardSOzgurogluMPrednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trialLancet201037697471147115420888992
   PubMed Web of Science ®Google Scholar
• De BonoJSOudardSOzgurogluMPrednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial3769747 Web Appendix 1
   Google Scholar
• NCCN Clinical Practice Guidelines in OncologyProstate Cancer22009 http://www.nccn.orgAccessed. 2009 Jul 29
   Google Scholar
• KellyWKHalabiSCarducciMAA randomized, double-blind, placebo-controlled phase III trial comparing docetaxel, prednisone, and placebo with docetaxel, prednisone, and bevacizumab in men with metastatic castration-resistant prostate cancer (mCRPC): survival results of CALGB 90401J Clin Oncol (Meeting Abstracts)201028Suppl 18LBA4511
   Web of Science ®Google Scholar
• NCT0617669: A phase III, randomised, double-blind, placebo-controlled study to assess the efficacy and safety of 10 mg ZD4054 (zibotentan) in combination with docetaxel in comparison with docetaxel in patients with metastatic hormone-resistant prostate cancer http://www.clinicaltrials.govAccessed 2010 Oct 7
   Google Scholar
• NCT0134056: Phase III study of docetaxel and atrasentan versus docetaxel and placebo for patients with advanced hormone refractory prostate cancer http://www.clinicaltrials.govAccessed 2010 Oct 7
   Google Scholar
• NCT0988208: A phase 3 study to evaluate the efficacy and safety of docetaxel and prednisone with or without lenalidomide in subjects with castrate-resistant prostate cancer http://www.clinicaltrials.govAccessed 2010 Oct 7
   Google Scholar
• NCT0430183: Randomized phase III study of neo-adjuvant docetaxel and androgen deprivation prior to radical prostatectomy versus immediate radical prostatectomy in patients with high-risk, clinically localized prostate cancer http://www.clinicaltrials.govAccessed 2010 Nov 7
   Google Scholar
• CulineSEl DemeryMLamyP-JIborraFAvancèsCPinguetFDocetaxel and cisplatin in patients with metastatic androgen independent prostate cancer and circulating neuroendocrine markersJ Urol2007178384484817631339
   PubMed Web of Science ®Google Scholar
• NCT1140607: Phase I safety and pharmacokinetic study of XRP6258 (cabazitaxel) in advanced solid tumor patients with varying degrees of hepatic impairment http://www.clinicaltrials.govAccessed 2010 Oct 5
   Google Scholar
• NCT0925743: A dose-escalation study of the safety, tolerability, and pharmacokinetics of cabazitaxel in combination with cisplatin administered every 3 weeks in subjects with advanced solid malignancies http://www.clinicaltrials.govAccessed 2010 Oct 5
   Google Scholar
• NCT1001221: A dose-escalation, single arm, combination study of cabazitaxel with gemcitabine to determine the safety, and pharmacokinetics in subjects with advanced solid malignancies http://www.clinicaltrials.govAccessed 2010 Oct 5
   Google Scholar
• NCT1087021: QT-Cab: an open-label study to investigate the effect of cabazitaxel on the QTc interval in cancer patients http://www.clinicaltrials.govAccessed 2010 Oct 5
   Google Scholar